Harvard Bioscience (NASDAQ:HBIO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.62) by 46.77 percent. This is a 230 percent decrease over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $20.755 million which missed the analyst consensus estimate of $21.200 million by 2.10 percent. This is a 4.68 percent decrease over sales of $21.774 million the same period last year.